Most in silico drug design technologies can generate compounds that either structurally fit a target or have desired activities. Numerate Inc.'s technology is able to do both, resulting in a greater variety of lead candidates that can provide its biotech and pharma clients a hedge against drug development risks like toxicity, clinical failures and IP crowding.

According to co-founder and CEO Guido Lanza, in silico design technologies come in two flavors: structure-based and data-driven.